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ABSTRACT 
Application of erythrocytes, the most abundant cells of the human body with desirable physiologic and 
morphologic characteristics, in drug delivery has been exploited extensively. Among the various carriers used 
for targeting drugs to various body tissues, the cellular carriers meet several criteria desirables in clinical 
applications, among the most important being biocompatibility of carrier and its degradation products. 
Leucocytes, platelets, erythrocytes, Nano erythrocytes, hepatocytes, and fibroblasts etc. have been proposed as 
cellular carrier systems. Among these, the erythrocytes have been the most investigated and have found to 
possess greater potential in drug delivery. Biopharmaceuticals, therapeutically significant peptides and proteins, 
nucleic acid-based biological, antigens, anticancer drug and vaccines, are among the recently focused 
pharmaceuticals for being delivered using carrier erythrocytes. Erythrocytes, also known as red blood cells, and 
have been extensively studied for their potential carrier capabilities for the delivery of drugs. The 
biocompatibility, non-pathogenicity, non-immunogenicity and biodegradability make them unique and useful 
carriers.  
Keywords: Resealed Erythrocytes, carrier, Isolation, Applications. 
INTRODUCTION  
The normal erythrocyte (normocyte) is a flexible, elastic, biconcave disc shaped structure with mean diameter 
7.3 μm and thickness near 2.2 μm. The chemical constituent of red blood cells include water (63%), lipids (0.5%), 
glucose (0.8%), minerals (0.7%), non-hemoglobin (33.67%). The primary function of the erythrocyte is transport 
of oxygen and carbon dioxide. Erythrocytes are the most abundant cells in the human body (5.4 million 
cells/mm3 blood in a healthy male and 4.8 million cells/mm3 blood in a healthy female).  
 
Figure 1: Composition of blood 
Erythrocytes live only about 120 days because of wear and tear on their plasma membranes. The process of 
erythrocyte formation within the body is known as erythropoiesis. In a mature human being, erythrocytes are 
produced in red bone marrow under the regulation of a hemopoietic hormone called erythropoietin. [1] 
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ERYTHROCYTES  
Red blood cells (also referred to as erythrocytes) are the most common type of blood cells and the vertebrate 
organism's principal means of delivering oxygen (O2) to the body tissues via the blood flow through the 
circulatory system. The cells develop in the bone marrow and circulate for about 100–120 days in the body 
before their components are recycled by macrophages. Each circulation takes about 20 seconds. Approximately 
a quarter of the cells in the human body are red blood cells. [2] 
                                     
 
Fig 2: Erythrocyte 
 THE ERYTHROCYTES MEMBRANE  
It contains about equal weight of proteins and lipids. The outer surface of membrane bears a net negative 
charge due largely to carboxylic groups of sialic acid. The isoelectric point is about pH 2 which is raised to 
pH4-5 after quantitative removal of the sialic acid with neural amidase. There is about 2.4×107 N-acetyl 
neuraminic acid residue per human erythrocyte. The negative surface charge prevents erythrocyte from 
coming into contact and maintains a sufficient distance between erythrocytes so that they cannot be readily 
agglutinated with IgG. [3]H  
 
 
E ERYTHEOCYTE MEMBRA NEE ETHE 
ERYTHEOCYTE MEMBRANER 
Figure 3: Basic structure of erythrocyte membrane 
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ADVANTAGES 
➢ Biocompatible, particularly when autologous cells are used hence no possibility of triggered immune   
response. 
➢ Biodegradability with no generation of toxic products. 
➢ Considerable uniform size and shape of carrier. 
➢ Relatively inert intracellular environment can be encapsulated in a small volume of cells. 
➢  Isolation is easy and large amount of drug can be loaded. 
➢ Prevention of degradation of the loaded drug from inactivation by endogenous chemical  
➢ Entrapment of wide variety of chemicals can be possible. 
➢ Entrapment of drug can be possible without chemical modification of the substance to be entrapped.  
➢ Possible to maintain steady-state plasma concentration, decrease fluctuation in concentration. 
➢ Protection of the organism against toxic effect of drug. 
➢ Targeting to the organ of the RES. 
➢ Ideal zero-order drug release kinetic. 
➢ Prolong the systemic activity of drug by residing for a longer time in the body.11-20 
DISADVANTAGES 
➢ They have a limited potential as carrier to non-phagocyte target tissue. 
➢ Possibility of clumping of cells and dose dumping may be there. 
ANATOMY PHYSIOLOGY AND COMPOSITION OF ERTHROCYTES  
RBCs have shapes like biconcave discs with a diameter of 7.8 μm and thickness near 2.2 μm. Mature RBCs have 
a simple structure. It is also in elastic in nature. Their plasma membrane is both strong and flexible, which allows 
them to deform without rupturing as they squeeze through narrow capillaries. RBCs are highly specialized for 
their oxygen transport function, because their mature RBCs have no nucleus, a ll their internal space is available 
for oxygen transport. Each RBC contains about 280 million hemoglobin molecules. A hemoglobin molecule  
consists of a protein called globin, composed of four polypeptide chains; a ring like non-protein pigment called 
a heme, is bound to each of the four chains. At the centers of the heme ring combine reversibly with one oxygen 
molecule, allowing each hemoglobin molecule to bind four oxygen molecules. RBCs include water (63%), lipids 
(0.5), glucose (0.8%), mineral (0.7%), non-hemoglobin protein (0.9%), methehemoglobin (0.5%), and hemoglobin 
(33.67%).[4] 
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ERYTHROCYTES CAN BE USED AS CARRIERS IN TWO WAYS  
Targeting particular tissue/organ  
For targeting, only the erythrocyte membrane is used. This is obtained by splitting the cell in hypotonic solution 
and after introducing the drug into the cells, allowing them to reseal into spheres. Such erythrocytes are called 
Red cell ghosts.  
Continuous or prolonged release of drugs  
Alternatively, erythrocytes can be used as a continuous or prolonged release system, which provide prolonged 
drug action. There are different methods for encapsulation of drugs within erythrocytes. They remain in the 
circulation for prolonged periods of time (up to 120 days) and release the entrapped drug at a slow and steady 
rate. [2] 
 
Fig 4: General mechanism of resealed erythrocytes 
ISOLATION OF ERYTHROCYTES 
• Blood is collected into heparin zed tubes by venipunture. 
• Blood is withdrawn from cardiac/splenic puncture (in small animal) and through veins (in large animals) 
in a syringe containing a drop of anti-coagulant. 
• The whole blood is centrifuged at 2500 rpm for 5 min. at 4 ±10C in a refrigerated centrifuge.  
•  The serum and Buffy coats are carefully removed and packed cells washed three Mtimes with phosphate 
buffer saline (pH=7.4). 
• The washed erythrocytes are diluted with PBS and stored at 40C for as long as 48 h before use.  
• Various types of mammalian erythrocytes have been used for drug delivery, including erythrocytes of 
mice, cattle, pigs, dogs, sheep, goats, monkeys, chicken, rats, and rabbits. [4] 
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Table1; Various condition and centrifugal force used for isolation of erythrocytes 
S.No.  Species Washing Buffer Centrifugal force (g) 
1. Rabbit  10mmol KH2PO4/NaHPO4 500-1000 
2. Dog  15mmol KH2PO4/NaHPO4 500-1000 
3. Human 154mmol NaCl <500 
4. Mouse  10mmol KH2PO4/NaHPO4 100-500 
5. Cow  10-15mmol KH2PO4/NaHPO4 1000 
6. Horse  2mmol MgCl2, 10mmol glucose 1000 
7. Sheep 10mmol KH2PO4/NaHPO4 500-1000 
8. pig 10mmol KH2PO4/NaHPO4 500-1000 
 
BASIC REQUIREMENT FOR ENCAPSULATION  
• The compounds which are showing therapeutic action (5000-60,000 daltons ) can be entraped 
or loaded in erythrocytes. 
• Non- polar molecules may be entrapped in the form of salts. Example: tetracycline HCl salt can 
be appreciably entrapped in bovine Red Blood Erythrocytes. 
• The compounds have either polar or non – polar molecules can have loaded in erythrocytes. 
• Some molecules are hydrophobic in nature there are loaded by absorbing over the molecules . 
• Charged molecules are stable long period of time when compared to uncharged molecule.  
• The size of the drug molecule is significantly larger than B – galactosidase [5] 
METHODS OF DRUG LOADING IN ERYTHROCYTES 
1. Hypo-osmotic lysis 
a) Dilution method 
b) Preswelling method 
c) Dialysis method 
d) Osmotic lysis method 
2. Membrane perturbation method 
3.  Electro encapsulation method 
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4.  Endocytosis method 
5. Lipid fusion method 
6. Electric cell fusion method 
7. Use of Red cell loader  
1. HYPO-OSMOTIC LYSIS METHOD:  
These are divided into four types are as follows- 
a) Hypotonic Dilution  
In this method, a volume of packed erythrocytes is diluted with 2–20 volumes of aqueous solution of a drug. 
The RBC’S are exposed to hypotonic solution (corresponding to 0.4% Nacl), the erythrocytic membrane ruptures 
permitting escape of cellular contents  
and equilibrium is achieved with in one minute. The cells swell up to 1.6 times its original volume indicated by 
formation of pores of size 200 – 500 Ao. The length of time for which these pores remain open is not fixed. 
However, at 0oC the opening permits long enough to allow partial resealing of membrane. Increasing ionic 
strength to isotonicity and incubating the cells at 37oC causes the pores to close and restore osmotic properties 
of the RBC’S. This method is simplest and fastest yet the capsulation efficacy is very low i. e. 1 – 8%. Efficient for 
of low weight drugs.  
Examples of encapsulated agents: β-glucosidase, asparaginase, arginase, salbutamol. 
 
Fig 5: Hypotonic Dilution Method 
b) Hypotonic preswell method  
The method was investigated by Rechsteiner in 1975 and was modified by Jenner et al for-drug loading. This 
method was based on the principle of first swelling the erythrocytes without lysis by placing them in slightly 
hypotonic solution. The swollen cells are recovered by centrifugation at low speed. Then, relatively small volumes 
of aqueous drug solution are added to the point of lysis. The slow swelling of cells results in good retention of 
the cytoplasmic constituents and hence good survival in vivo. This method is simpler and faster than other 
methods, causing minimum damage to cells.  
Examples of encapsulated agents: Propranolol, asparginase, methotrexate, isoniazid etc.  
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Fig 6: Hypotonic preswell Method 
c) Hypotonic Dialysis  
This method was first reported in 1959 by Klibansky and was used in 1977 by Deloach and Ihler and in 1989 by 
Gaudreault RC for loading enzymes and lipids. A desired Haematocrit is achieved by mixing washed erythrocyte 
suspension and phosphate buffer (pH 7.4) containing drug solution. This mixture is placed  into dialysis bag and 
then both ends of the bag are tied with thread. An air bubble of nearly 25% of the internal volume is left in the 
tube. During dialysis bubble serves to blend the content. The tube is placed in a bottle containing 200ml of lysis 
buffer solution and placed on a mechanical rotator at 4oC for 2 hrs. The dialysis tube is then placed in 200 ml 
of resealing solution (isotonic PBS pH 7.4) at temperature 25 – 30oC for resealing. The loaded erythrocytes thus 
obtained are then washed with cold PBC at 4oC. The cells are finally resuspended in PBC.  
Examples of encapsulated agents: Gentamicin, adriamycine, erythropoietin, furamycin A, IgG etc  
 
 
Fig 7: Hypotonic Dialysis Method 
d) Isotonic osmotic lysis  
This method, also known as the osmotic pulse method, involves isotonic hemolysis. Erythrocytes incubated in 
solutions of a substance with high membrane permeability; the solute will diffuse into the cells because of the 
concentration gradient. Chemicals such as urea solution, polyethylene glycol, ammonium chloride and dimethyl 
sulfoxide (DMSO) have been used for isotonic hemolysis.  
Examples of enc apsulated agents: Inositol hexaphosphate  
                                                     
To Chemistry Journal Vol 1 No 2 (2018) ISSN: 2581-7507                                                 http://purkh.com/index.php/tochem 
8 
 
Fig 8: Isotonic Osmotic Lysis Method 
2. CHEMICAL PERTURBATION OF THE MEMBRANE  
This method is based on the increase in membrane permeability of erythrocytes when the cells are exposed to 
certain chemicals. In 1973, Deuticke showed that the permeability of erythrocytic membrane increases upon 
exposure to polyene antibiotic such as amphotericin B. The method was used successfully by Kitao and Hattori 
to entrap the antineoplastic drug daunomycin in human and mouse erythrocytes in 1980. Lin et al. used 
halothane for the same purpose. However, these methods induce irreversible destructive changes in the cell 
membrane and hence are not very popular.  
Examples of encapsulated agents: Daunomycin 
 
Fig 9: Drug loaded by perturbation method 
3. ELECTRICAL BREAKDOWN METHOD/ ELECTOENCAPSULATION  
When the membrane is polarized very rapidly (in nano to micro seconds) using voltage of about 2kV/ cm for 
20μ sec electrical breakdown of a cell membrane is observed which leads to the formation of pores and 
entrapment of drugs. Electrical breakdown probably takes place in the lipoid regions or at the lipid protein 
junction in the membrane. Pores formed are stable and it is possible to control pore size. Subsequently the 
pores can be resealed by incubation at 37ºC in osmotically balanced medium.  
Examples of encapsulated agents: Primaquine and related 8–amino–quinolines, vinblastine, chlorpromazine and 
related phenothiazines, hydrocortisone, propranolol, vitamin A etc. 
To Chemistry Journal Vol 1 No 2 (2018) ISSN: 2581-7507                                                 http://purkh.com/index.php/tochem 
9 
 
Fig 10: Drug loaded by electro encapsulation technique 
4. ENDOCYTOSIS  
This method was reported by Schrier (1987). Endocytosis involves the addition of one volume of washed packed 
erythrocytes to nine volumes of buffercontaining2.5 mm ATP, 2.5 mm MgCl2 and 1mM CaCl2, followed by 
incubation for2 min at room temperature. The pores created by this method are resealed by using 154 mm of 
Nacl and incubation at 370c for 2 min. The entrapment of material occurs by endocytosis. The vesicle membrane 
separates endocytosed material from cytoplasm thus protecting it from the erythrocytes and vice-versa.  
Examples of encapsulated agents. Hydrocortisone, propranolol, vitamin A Primaquine, vinblastine, 
chlorpromazine etc 
            
 
Fig 11: Drug loaded by Endocytosis 
5. LOADING BY LIPID FUSION  
In this method fused lipid vesicle containing bioactive molecule along with human erythrocytes leading to 
exchange of lipid entrapped drug molecule. This method provides very low encapsulation efficiency. Nicola and 
Gresonde fused lipid vesicle containing inositol hexaphosphate with human erythrocytes. The incorporated 
inositol hexaphosphate in erythrocytes provided a significant lowering of the oxygen affinity for hemoglobin in 
intact erythrocytes. Harrison et al reported resealing of tyrosine kinase into human erythrocytes by rapid freezing 
and thawing in liquid.  
Examples of encapsulated agents: Inositol monophosphate. 
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6. LOADING BY ELECTRIC CELL FUSION  
This method involves the initial loading of drug molecules into erythrocyte ghosts followed by adhesion of these 
cells to target cells. The fusion is accentuated by the application of an electric pulse, which causes the release of 
an entrapped molecule. An example of this method is loading a cell-specific monoclonal antibody  
into an erythrocyte ghost. An antibody against a specific surface protein of target cells can be chemically cross-
linked to drug-loaded cells that would direct these cells to desired cells.                    
USE OF RED CELL LOADER  
Magnani and coworkers, 1998 developed a novel method for the entrapment of non-diffusible drugs into human 
erythrocytes. The equipment designed for this method was termed as “red cell loader”. The method requires as 
little as 50ml of blood sample, different biologically active compounds were entrapped into erythrocytes within 
a period of 2 h at room temperature under blood banking conditions. The process is based on two sequential 
hypotonic dilutions of washed erythrocytes followed by concentration with a hem filter and an isotonic r esealing 
of the cells.  
There was 30% drug loading with 35–50% cell recovery. The processed erythrocytes had normal survival in vivo. 
The same cells could be used for targeting by improving their recognition by tissue macrophages. [6,7,8,9,10] 
 
 
Fig.No.12 Use of Red Cell Loader 
CONCLUSION  
This review focuses on appropriateness of erythrocytes as biological carriers. It shows that some of the various 
latent biomedical applications of RBCs based drug delivery systems opening new perspectives to the vision of 
using our cells for salutary purposes. Thus, the resealed erythrocyte is the promising carrier for various drugs, 
therapeutic proteins, a vaccine for both targeting and delivery. However, the concept needs further optimization 
to become a custom drug delivery system. Most of the studies in this area are in the in vitro phase and the 
ongoing projects worldwide stay behind to step into preclinical and, then, clinical studies to prove the 
capabilities of this promising delivery system. 
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